Novo Nordisk Fights Hundreds of Lawsuits While Racing to Outrun Its Own Patent Cliff

Novo Nordisk confronts hundreds of NAION vision-loss lawsuits and pipeline skepticism after an 8% stock drop on its 2030 outlook.

Novo Nordisk is simultaneously battling a swelling wave of product-liability litigation and mounting skepticism over whether its drug pipeline can plug the revenue hole left by expiring patents. The Danish drugmaker confirmed on Tuesday that it faces hundreds of lawsuits from patients who claim they were not adequately warned about the risk of sudden vision loss tied to diabetes and weight-loss treatments.

Plaintiffs say they were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), a condition affecting the optic nerve that can cause abrupt and frequently irreversible sight loss. Novo Nordisk rejected the allegations outright, stating there is no significant link between its medicines and vision loss. In comments to NBC, the company reaffirmed the safety profile of its products and said it intends to defend itself vigorously in court. Eli Lilly, its U.S. rival, is named alongside Novo Nordisk in the claims.

A Capital Markets Day That Missed the Mark

The legal pressure lands at an awkward moment. Just a day earlier, management had laid out its strategic ambitions through 2030 at a capital markets day in London — an event that left the market underwhelmed. For the 2026–2030 stretch, the company projected revenue growth that will likely converge with the average pace of the global pharmaceutical industry, a signal that its expansion engine is decelerating. Investors reacted coolly, and the stock dropped 8% immediately after the presentation.

Chief executive Mike Doustdar used the event to promise at least five blockbuster medicines with billion-dollar potential by 2030, part of an effort to shore up Novo Nordisk's position in metabolic disease. The company is also targeting risk-adjusted pipeline revenue of more than DKK 150 billion by 2035.

Clinical Data Offer a Counterweight

The optimism rests heavily on the next generation of obesity therapies. In the REIMAGINE-5 trial, the candidate CagriSema delivered 12.4% weight loss in adults with type 2 diabetes at week 60, against 9.1% for Eli Lilly's Tirzepatid — while also achieving a non-inferior reduction in HbA1c. A separate study, REDEFINE-9, showed 21% weight loss in overweight or obese adults after 68 weeks, compared with just 2.0% in the placebo arm.

Beyond obesity, Novo Nordisk has logged progress in rare diseases. One of its products is the first factor VIIIa mimetic to offer flexible dosing intervals in a prefilled pen.

Analysts Trim Targets as Competition Builds

Sell-side sentiment has turned cautious. Deutsche Bank cut its price target to DKK 245 from DKK 265, keeping a sell rating. Jefferies reportedly lowered its target to DKK 275 from DKK 285 while maintaining a hold recommendation. The concern is that Novo Nordisk could lose pricing power in its core diabetes and obesity markets as rivals such as Eli Lilly press their own offerings, and as the looming patent expiry on blockbuster Semaglutide opens the door to generic competition. If copycat treatments arrive faster than the new pipeline candidates generate sales, current margins would come under threat.

Buyback Continues Amid the Turmoil

Even as the share price struggles, the company is pressing ahead with capital returns. Between February 4 and September 18, Novo Nordisk repurchased 34,174,179 of its own B shares for a total transaction volume of DKK 9.63 billion.

The stock closed Wednesday at EUR 33.66, down 2.2%. Over the past seven days it has shed 12%, and it now sits 40% below its 52-week high. Year-to-date, the decline stands at 24%.

The Levels That Matter Now

Technically, the picture hinges on the 52-week low of EUR 30.25. Holding above that threshold could allow the shares to stabilize, with investors rewarding progress on CagriSema's clinical development and the long-term pipeline roadmap. A sustained break below it, however, would risk extending the correction as the market prices in a deeper hit to future earnings.

The next tangible catalyst for reassessing growth prospects will likely be further advances in CagriSema's regulatory filings. Investors must now weigh whether pipeline wins carry more weight than the concrete transition risks looming before the decade is out.